Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.

Brane Grambozov; Forough Kalantari; Mohsen Beheshti; Markus Stana; Josef Karner; Elvis Ruznic; Barbara Zellinger; Felix Sedlmayer; Gabriel Rinnerthaler; Franz Zehentmayr

doi:10.1016/j.radonc.2023.109728

Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.

Brane Grambozov^* (First author), Forough Kalantari (Co-author), Mohsen Beheshti (Co-author), Markus Stana (Co-author), Josef Karner (Co-author), Elvis Ruznic, Barbara Zellinger (Co-author), Felix Sedlmayer (Co-author), Gabriel Rinnerthaler (Co-author), Franz Zehentmayr (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article › peer-review

5 Citations (Web of Science)

Original language	English
Pages (from-to)	109728
Journal	RADIOTHERAPY AND ONCOLOGY
Volume	185
DOIs	https://doi.org/10.1016/j.radonc.2023.109728
Publication status	Published - 2023

Keywords

CELL LUNG-CANCER
POSITRON-EMISSION-TOMOGRAPHY
DEFINITIVE CHEMORADIATION THERAPY
STANDARDIZED UPTAKE VALUE
METABOLIC TUMOR VOLUME
LOCAL-CONTROL
F-18-FDG PET
RADIOTHERAPY
SURVIVAL
STAGE

Access to Document

10.1016/j.radonc.2023.109728

Cite this

Grambozov, B., Kalantari, F., Beheshti, M., Stana, M., Karner, J., Ruznic, E., Zellinger, B., Sedlmayer, F., Rinnerthaler, G., & Zehentmayr, F. (2023). Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy. RADIOTHERAPY AND ONCOLOGY, 185, 109728. https://doi.org/10.1016/j.radonc.2023.109728

@article{0e398b332843456f8f601575a4dde86e,

title = "Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.",

keywords = "CELL LUNG-CANCER, POSITRON-EMISSION-TOMOGRAPHY, DEFINITIVE CHEMORADIATION THERAPY, STANDARDIZED UPTAKE VALUE, METABOLIC TUMOR VOLUME, LOCAL-CONTROL, F-18-FDG PET, RADIOTHERAPY, SURVIVAL, STAGE",

author = "Brane Grambozov and Forough Kalantari and Mohsen Beheshti and Markus Stana and Josef Karner and Elvis Ruznic and Barbara Zellinger and Felix Sedlmayer and Gabriel Rinnerthaler and Franz Zehentmayr",

note = "Grambozov: Department of Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria; Kalantari: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria; Behesti: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria; Stana, Karner, Ruznic: Department of Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria; Zellinger: Institute of Pathology, Paracelsus Medical University, SALK, Salzburg, Austria; Sedlmayer, Zehentmayr: Department of Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria; radART - Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria; Rinnerthaler: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Cancer Cluster Salzburg, 5020 Salzburg, Austria",

year = "2023",

doi = "10.1016/j.radonc.2023.109728",

language = "English",

volume = "185",

pages = "109728",

journal = "RADIOTHERAPY AND ONCOLOGY",

issn = "0167-8140",

publisher = "Elsevier ",

}

Grambozov, B, Kalantari, F, Beheshti, M , Stana, M , Karner, J, Ruznic, E, Zellinger, B, Sedlmayer, F, Rinnerthaler, G & Zehentmayr, F 2023, 'Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.', RADIOTHERAPY AND ONCOLOGY, vol. 185, pp. 109728. https://doi.org/10.1016/j.radonc.2023.109728

Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy. / Grambozov, Brane (First author); Kalantari, Forough (Co-author); Beheshti, Mohsen (Co-author) et al.
In: RADIOTHERAPY AND ONCOLOGY, Vol. 185, 2023, p. 109728.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.

AU - Grambozov, Brane

AU - Kalantari, Forough

AU - Beheshti, Mohsen

AU - Stana, Markus

AU - Karner, Josef

AU - Ruznic, Elvis

AU - Zellinger, Barbara

AU - Sedlmayer, Felix

AU - Rinnerthaler, Gabriel

AU - Zehentmayr, Franz

N1 - Grambozov: Department of Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria; Kalantari: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria; Behesti: Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria; Stana, Karner, Ruznic: Department of Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria; Zellinger: Institute of Pathology, Paracelsus Medical University, SALK, Salzburg, Austria; Sedlmayer, Zehentmayr: Department of Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria; radART - Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Austria; Rinnerthaler: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Cancer Cluster Salzburg, 5020 Salzburg, Austria

PY - 2023

Y1 - 2023

KW - CELL LUNG-CANCER

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - DEFINITIVE CHEMORADIATION THERAPY

KW - STANDARDIZED UPTAKE VALUE

KW - METABOLIC TUMOR VOLUME

KW - LOCAL-CONTROL

KW - F-18-FDG PET

KW - RADIOTHERAPY

KW - SURVIVAL

KW - STAGE

U2 - 10.1016/j.radonc.2023.109728

DO - 10.1016/j.radonc.2023.109728

M3 - Original Article

C2 - 37301259

SN - 0167-8140

VL - 185

SP - 109728

JO - RADIOTHERAPY AND ONCOLOGY

JF - RADIOTHERAPY AND ONCOLOGY

ER -